Compare CRSP & NG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | NG |
|---|---|---|
| Founded | 2013 | 1984 |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.7B |
| IPO Year | 2016 | 2002 |
| Metric | CRSP | NG |
|---|---|---|
| Price | $46.38 | $8.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | ★ $70.29 | $11.63 |
| AVG Volume (30 Days) | 2.0M | ★ 3.7M |
| Earning Date | 05-05-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $1,082.59 | N/A |
| Revenue Next Year | $87.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $30.06 | $2.26 |
| 52 Week High | $78.48 | $14.40 |
| Indicator | CRSP | NG |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 33.33 |
| Support Level | N/A | $7.97 |
| Resistance Level | $60.63 | $10.61 |
| Average True Range (ATR) | 2.30 | 0.74 |
| MACD | -0.84 | -0.49 |
| Stochastic Oscillator | 10.22 | 9.53 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other precious metals.